This website is intended for healthcare professionals
This website is intended for healthcare professionals
Volume 4 | Issue 4
ISSN (Print): 2631-8385
ISSN (Online): 2631-8393
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved tixagevimab/cilgavimab (Evusheld), a new monoclonal antibody combination, for COVID-19 pre-exposure prophylaxis, or administration to people at risk before they are exposed to COVID-19 infection in order to prevent disease..
